Andrea S. Blevins Primeau, PhD, MBA

Cancer drugs that are granted accelerated approval are less likely than drugs with regular approval to be given high-level evidence ratings and preferred status in NCCN guidelines, a new study suggests.

Researchers sought to determine whether CLAG conditioning would be effective prior to allogeneic HSCT in patients with AML.

Adding atezolizumab to bevacizumab and platinum-based chemotherapy can improve outcomes in patients with metastatic, persistent, or recurrent cervical cancer, a phase 3 trial suggests.

Researchers found modest decreases in the risk of breast cancer-specific death and all-cause death among patients who used vaginal estrogen therapy.

Researchers sought to determine whether early relapse in multiple myeloma would be prognostic of early progression and risk.

Adding docetaxel to standard treatment can prolong prostate cancer-specific survival in certain patients, a meta-analysis suggests.

Cabozantinib improved progression-free survival in a phase 3 trial of patients with previously treated, pancreatic or extrapancreatic NETs.

Combination treatment with avelumab and regorafenib has shown activity in patients with relapsed/refractory gastrointestinal stromal tumors.

Adding toripalimab to chemotherapy improves progression-free and overall survival in patients with newly diagnosed ES-SCLC, a phase 3 trial suggests.

Coverage determination for oncology drugs can be delayed for months after regulatory approval, a new study suggests.